MedImmune
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, MedImmune sits in the top decile of US sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count).
MedImmune: 210 sponsored US clinical trials, none currently recruiting.
MedImmune sponsors 210 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 185 completed. 27 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.
Top-decile sponsor footprint
MedImmune ranks in the top decile of sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
185 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
210 total, page 3 of 5
A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis
NCT01209585
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
NCT01352884
A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
NCT01268072
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
NCT01268566
A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma
NCT01334853
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
NCT01268059
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
NCT01238861
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
NCT01284231
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01227278
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
NCT01248949
A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
NCT00979654
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
NCT01455402
A Clinical Study to Assess the Safety of a New Influenza Vaccine
NCT01104493
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
NCT01127321
A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies
NCT00983619
A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects
NCT01093040
A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
NCT00946699
A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children
NCT01091246
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
NCT01030536
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
NCT00968669
A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma
NCT00930683
An Observational Study to Assess Respiratory Syncytial Virus (RSV) Respiratory Events Among Premature Infants
NCT00983606
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
NCT00946101
A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults
NCT00945893
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age
NCT00952705
Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors
NCT00796055
A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine
NCT00873912
A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors
NCT00816361
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.
NCT00816400
A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age
NCT00860067
A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).
NCT00768079
A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma
NCT00783289
Respiratory Events Among Premature Infants
NCT00889070
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children
NCT00767416
Assessing Choice in the Employer Setting (ACES) Study
NCT00808808
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
NCT00659425
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
NCT00657189
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
NCT00677820
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
NCT00686075
A Study to Assess Bioavailability and Pharmacokinetics of CAT- 354
NCT00638989
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
NCT00533091
A Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma
NCT00590720
A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma
NCT00659659
A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557
NCT00578682
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
NCT00626808
A Post Marking Study to Evaluate the Safety of FluMist in Children
NCT00569894
A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of Age
NCT00508651
A Study to Describe Pediatric Influenza Vaccine Coverage
NCT00639418
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
NCT00587015
A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
NCT00507130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 58 |
| Phase 3 | 12 |
| Phase 4 | 15 |
How the MedImmune early-phase archive is shaped
210 indexed studies, none listed as recruiting (0% open); 185 completed (88%).
Phase mix: 27 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Healthy (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
MedImmune: archived-pipeline peers nationwide
Peers matched on 210 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 210 archived trials
- OHSU Knight Cancer Institute · 211 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this MedImmune page
210 registered trials is a research-attention snapshot, not an endorsement of MedImmune or any single study.
- None of MedImmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition MedImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
MedImmune pipeline card: 210 registered trials from official public datasets.Report a data error.